Aurinia Pharmaceuticals (AUPH) Interest Expenses (2018 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Interest Expenses came in at $1.0 million in Q1 2026, down 98.77% YoY from $82.3 million in Q1 2025, and up 146.36% on a QoQ basis from -$2.2 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Interest Expenses (2018 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 9 years of Interest Expenses data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Interest Expenses fell 98.77% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.5 million (down 104.21% YoY) and the FY2025 annual result came in at $54.1 million, down 64.99% from the prior year.
- Interest Expenses climbed to $1.0 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $92.9 million in Q2 2024 to a low of -$2.6 million in Q4 2024.
- A 5-year average of $18.5 million and a median of $1.4 million in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 142880.0% in 2024, down 977.63% in 2024.
- Tracing AUPH's Interest Expenses over 5 years: stood at $1.2 million in 2022, then slumped by 75.42% to $295000.0 in 2023, then sank by 977.63% to -$2.6 million in 2024, then increased by 15.68% to -$2.2 million in 2025, then soared by 146.36% to $1.0 million in 2026.
- The last three Interest Expenses figures came in at $1.0 million (Q1 2026), -$2.2 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn | 67.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 67.17 Mn |
| Jun 30, 2026 | 67.17 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | 7.18 Mn |
| Sep 30, 2025 | 7.18 Mn |
| Jun 30, 2025 | 7.47 Mn |
| Jun 30, 2025 | 7.47 Mn |
| Mar 31, 2025 | 82.28 Mn |
| Mar 31, 2025 | 82.28 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 92.94 Mn |
| Jun 30, 2024 | 92.94 Mn |
| Mar 31, 2024 | 8.88 Mn |
| Mar 31, 2024 | 8.88 Mn |